Utility of apremilast in the treatment of psoriasis
Psoriasis is an autoimmune disease that affects more than one bodily system with predominantly skin and also joint manifestations affecting almost 2% of the world population that occurs primarily due to immune dysregulation. Apremilast is an oral, selective inhibitor of phosphodiesterase-4 (PDE4) enzymes. Inhibition of PDE-4 results in specific elevation of cAMP, an innately occurring intracellular secondary messenger that functions as a modulator of inflammatory responses. The drug is taken orally in strengths of 10, 20 and 30 mg. The drug may be a suitable alternative to different systemic therapies. Apremilast is a much-needed molecule for the treatment of psoriasis that is resistant to first line therapy and also useful in combination therapies.
John W. Ely, And Mary Seabury Stone, The generalized rash: Part II. Diagnostic approach. Am Fam Physician. 2010 Mar 15;81(6):735-9.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Aca Dermatol. 2008 May 1;58(5):826-50.
Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis. J Euro Aca Dermatol Venereol. 2018 Feb 1.
Bubna AK. Apremilast: A dermatologic perspective. Indian J Drugs Dermatol. 2016;2:75-82.
Vangipuram R, Alikhan A. Apremilast for the management of moderate to severe plaque psoriasis. Expert review clinical Pharmacol. 2017;10(4):349-60.
Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983-94.
Europe Medicines Agencies. Assessment report: Otezla, International non-proprietary name: apremilast. Available at: http://www.ema.europa.eu /d ocs/en_GB/document_library/EPAR_-_Public_ asses sment_report/human/003746/WC500182629.pdf.
Oral otezla (apremilast) approved by the U.S. Food and drug administration for the treatment of patients with moderate to severe plaque psoriasis. Available at: http://ir.celgene.com/releasedetail.cfm?releaseid=872240. Retrieved 29 October 2014.
Sumantran VN, Mishra P, Bera R, Sudhakar N. Microarray analysis of differentially-expressed genes encoding CYP450 and phase II drug metabolizing enzymes in psoriasis and melanoma. Pharmaceutics. 2016 Feb 17;8(1):4.
Deeks ED-Apremilast: A review in psoriasis and psoriatic arthritis Drugs. 2015;75(12):1393-403.
Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. American journal of clinical dermatology. 2017 Jun:1-0.
Australian public assessment report for apremilast proprietary product name: Otezla, PM-2013-04920-1-3. Available at: https://www.tga.gov.au/sites/default/files/auspar-apremilast-151022.pdf
Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Aca Dermatol. 2017 Aug 1;77(2):310-7.
Cather JC, Horn EJ. Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. Clin Inves. 2015 Sep;5(9):777-91.
Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 2012 Aug 25;380(9843):738-46.
Medscape. Otezla (aprelimast) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/otezla-apremilast-999915.
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE). J Euro Aca Dermatol Venereol. 2017 Mar;31(3):507-17.
RxList. Otezla (apremilast tablets): Side effects, interactions, warning, dosage and uses. Available from: https://www.rxlist.com/otezla-drug.htm#side_ effects_interactions.
EMC. Otezla 30mg tablets-summary of product characteristics (smpc)-(emc). Available at: https://www.medicines.org.uk/emc/product/3648.
Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. Pharmacy and Therapeutics. 2015 Aug;40(8):495.